- Home
- INO vs FATE Comparison
INO vs FATE Comparison
Compare INO & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INO | FATE |
|---|---|---|
| Founded | 1979 | 2007 |
| Country | United States | United States |
| Employees | N/A | 181 |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 136.6M | 115.1M |
| IPO Year | 1998 | 2013 |
Fundamental Metrics
Financial Performance| Metric | INO | FATE |
|---|---|---|
| Price | $1.75 | $0.97 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 7 |
| Target Price | ★ $9.00 | $3.92 |
| AVG Volume (30 Days) | ★ 1.7M | 1.4M |
| Earning Date | 11-10-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $182,337.00 | ★ $7,137,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $21,214.02 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.30 | $0.66 |
| 52 Week High | $2.98 | $1.99 |
Technical Indicators
Market Signals| Indicator | INO | FATE |
|---|---|---|
| Relative Strength Index (RSI) | 37.10 | 37.81 |
| Support Level | $2.11 | $0.98 |
| Resistance Level | $2.37 | $1.12 |
| Average True Range (ATR) | 0.19 | 0.07 |
| MACD | -0.05 | -0.01 |
| Stochastic Oscillator | 6.16 | 8.33 |
Price Performance
Historical ComparisonAbout INO Inovio Pharmaceuticals Inc.
Inovio Pharmaceuticals Inc is a United States-based biotechnology company. The company is focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.